EP0709099A3
(en)
*
|
1994-09-28 |
1996-07-24 |
Senju Pharma Co |
An aqueous nasal suspension comprising cyclodextrin
|
ZA959469B
(en)
*
|
1994-11-15 |
1996-05-15 |
South African Druggists Ltd |
Pharmaceutical composition
|
US5468502A
(en)
*
|
1994-12-20 |
1995-11-21 |
American Home Products Corporation |
Ibuprofen enhancing solvent system
|
AU5774796A
(en)
*
|
1995-06-13 |
1997-01-09 |
Dyer, Alison Margaret |
Pharmaceutical compositions containing lornoxicam and cyclod extrin
|
JP2000509374A
(en)
|
1996-04-19 |
2000-07-25 |
アルファ セラピュティック コーポレイション |
Method for virus inactivation of lyophilized blood proteins
|
UA57734C2
(en)
|
1996-05-07 |
2003-07-15 |
Пфайзер Інк. |
Arylheterocyclic inclusion complexes
|
US5906981A
(en)
*
|
1996-06-04 |
1999-05-25 |
Troy Corporation |
Halopropargyl inclusion complexes
|
DK0877600T3
(en)
*
|
1996-08-09 |
2004-02-02 |
Alcon Mfg Ltd |
Preservation system for pharmaceutical preparations containing cyclodextrin
|
DE19716120A1
(en)
*
|
1997-04-17 |
1998-10-22 |
Europ Lab Molekularbiolog |
Use of cholesterol-lowering agents
|
US6046177A
(en)
*
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
US5874418A
(en)
*
|
1997-05-05 |
1999-02-23 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
|
ATE253941T1
(en)
*
|
1997-06-13 |
2003-11-15 |
Cydex Inc |
COMPOSITION WITH INCREASED STORAGE STABILITY CONTAINING CYCLODEXTRIN AND ACTIVE INGREDIENTS OR ACTIVE INGREDIENTS WHICH ARE DECOMPOSED INTO WATER-INSOLUBLE COMPONENTS
|
GB9713149D0
(en)
*
|
1997-06-21 |
1997-08-27 |
Pfizer Ltd |
Pharmaceutical formulations
|
DE69834154T2
(en)
*
|
1997-07-01 |
2007-01-25 |
Pfizer Products Inc., Groton |
Process for the preparation of a cyclodextrin
|
EP1029872A4
(en)
*
|
1997-11-07 |
2001-05-02 |
Daiichi Seiyaku Co |
Piperazine-cyclodextrin complexes
|
WO1999042111A1
(en)
*
|
1998-02-23 |
1999-08-26 |
Cyclops, Ehf. |
High-energy cyclodextrin complexes
|
US6699849B1
(en)
|
1998-02-23 |
2004-03-02 |
Cyclops, Ehf. |
Cyclodextrin complexes of benzodiazepines
|
WO2000012137A1
(en)
*
|
1998-09-02 |
2000-03-09 |
Allergan Sales, Inc. |
Preserved cyclodextrin-containing compositions
|
FR2784584B1
(en)
*
|
1998-10-14 |
2002-09-20 |
Adir |
PROCESS FOR THE PREPARATION OF A NASAL SPRAY SOLUTION CONTAINING ONE OR MORE SEXUAL HORMONES AND A CYCLODEXTRIN
|
JP2002531530A
(en)
*
|
1998-12-04 |
2002-09-24 |
カリフォルニア インスティテュート オブ テクノロジー |
Supramolecular complexes containing therapeutic agents
|
US7375096B1
(en)
|
1998-12-04 |
2008-05-20 |
California Institute Of Technology |
Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
|
CA2359646C
(en)
|
1999-01-21 |
2008-12-02 |
Bristol-Myers Squibb Company |
Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-.beta.-cyclodextrin or 2-hydroxypropyl-.beta.-cyclodextrin and method
|
GB9913932D0
(en)
|
1999-06-15 |
1999-08-18 |
Pfizer Ltd |
Purine derivatives
|
GB9915231D0
(en)
|
1999-06-29 |
1999-09-01 |
Pfizer Ltd |
Pharmaceutical complex
|
CA2315614C
(en)
|
1999-07-29 |
2004-11-02 |
Pfizer Inc. |
Pyrazoles
|
GB9924363D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Central Res |
Purine derivatives
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
WO2001030391A2
(en)
*
|
1999-10-27 |
2001-05-03 |
Farmarc Nederland Bv |
Pharmaceutical composition containing midazolam
|
WO2001072338A1
(en)
*
|
2000-03-28 |
2001-10-04 |
Farmarc Nederland Bv |
Alprazolam inclusion complexes and pharmaceutical compositions thereof
|
ATE416791T1
(en)
|
2000-05-02 |
2008-12-15 |
Theravance Inc |
COMPOSITION CONTAINING A CYCLODEXTRIN AND A GLYCOPEPTIDE ANTIBIOTIC
|
US6667314B2
(en)
|
2000-05-26 |
2003-12-23 |
Pfizer, Inc. |
Tropane derivatives useful in therapy
|
AU5248201A
(en)
|
2000-05-26 |
2001-12-03 |
Manoussos Perros |
Tropane derivatives useful in therapy
|
US6753322B2
(en)
|
2000-06-06 |
2004-06-22 |
Pfizer Inc |
2-aminocarbonyl-9H-purine derivatives
|
US6921753B2
(en)
|
2000-06-27 |
2005-07-26 |
Pfizer Inc |
Purine derivatives
|
US6468989B1
(en)
|
2000-07-13 |
2002-10-22 |
Dow Pharmaceutical Sciences |
Gel compositions containing metronidazole
|
US6420557B1
(en)
|
2000-07-28 |
2002-07-16 |
Pfizer Inc. |
Crystalline therapeutic agent
|
US8980290B2
(en)
|
2000-08-03 |
2015-03-17 |
Antares Pharma Ipl Ag |
Transdermal compositions for anticholinergic agents
|
US7198801B2
(en)
|
2000-08-03 |
2007-04-03 |
Antares Pharma Ipl Ag |
Formulations for transdermal or transmucosal application
|
KR100856523B1
(en)
*
|
2000-08-03 |
2008-09-04 |
안타레스 파르마 아이피엘 에이쥐 |
Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
|
PE20020300A1
(en)
*
|
2000-08-22 |
2002-05-10 |
Pharmacia Corp |
COMPOSITION OF SOLUTION OF AN ANTIBIOTIC DRUG BASED ON OXAZOLIDINONE WITH IMPROVEMENT OF DRUG LOAD
|
GB0022695D0
(en)
|
2000-09-15 |
2000-11-01 |
Pfizer Ltd |
Purine Derivatives
|
PE20020578A1
(en)
|
2000-10-10 |
2002-08-14 |
Upjohn Co |
A TOPICAL ANTIBIOTIC COMPOSITION FOR THE TREATMENT OF EYE INFECTIONS
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
US6566556B2
(en)
*
|
2000-12-19 |
2003-05-20 |
Nippon Shokubai Co., Ltd. |
Method for production of alkanolamine and apparatus therefor
|
JP2005503446A
(en)
|
2001-01-11 |
2005-02-03 |
イーストマン ケミカル カンパニー |
Cyclodextrin sulfonate, guest inclusion complex, production method thereof and related substances
|
US20020146409A1
(en)
*
|
2001-01-30 |
2002-10-10 |
Herring Steven W. |
Methods for stabilizing lyophilized blood proteins
|
IL141647A0
(en)
*
|
2001-02-26 |
2002-03-10 |
Yeda Res & Dev |
Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
|
US6579898B2
(en)
|
2001-03-01 |
2003-06-17 |
Pfizer Inc. |
Compositions having improved bioavailability
|
US7034013B2
(en)
*
|
2001-03-20 |
2006-04-25 |
Cydex, Inc. |
Formulations containing propofol and a sulfoalkyl ether cyclodextrin
|
PT1377556E
(en)
|
2001-04-10 |
2007-06-06 |
Pfizer Ltd |
Pyrazole derivatives for treating hiv
|
WO2002087546A2
(en)
*
|
2001-05-01 |
2002-11-07 |
Pfizer Products Inc. |
Method for manufacturing a low dose pharmaceutical composition
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
EP1269994A3
(en)
*
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmaceutical compositions comprising drug and concentration-enhancing polymers
|
US7008934B2
(en)
*
|
2001-06-28 |
2006-03-07 |
Baxter International Inc. |
Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins
|
MXPA03011793A
(en)
*
|
2001-06-29 |
2004-04-02 |
Maxygen Holdings Ltd |
Interferon formulations.
|
GB0116453D0
(en)
|
2001-07-05 |
2001-08-29 |
Imp College Innovations Ltd |
Method
|
EP1411915A2
(en)
*
|
2001-07-20 |
2004-04-28 |
Dynamit Nobel GmbH |
Nitrate ester-cyclodextrin complexes for treating diseases, particularly coronary diseases
|
US6653339B2
(en)
|
2001-08-15 |
2003-11-25 |
Pfizer Inc. |
Method of treating irritable bowel syndrome
|
US7141540B2
(en)
*
|
2001-11-30 |
2006-11-28 |
Genta Salus Llc |
Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
|
GB0129273D0
(en)
|
2001-12-06 |
2002-01-23 |
Pfizer Ltd |
Crystalline drug form
|
US6881726B2
(en)
|
2001-12-24 |
2005-04-19 |
Dow Pharmaceutical Sciences |
Aqueous compositions containing metronidazole
|
KR20040083493A
(en)
|
2002-02-01 |
2004-10-02 |
화이자 프로덕츠 인크. |
Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
|
AU2003245711A1
(en)
|
2002-02-11 |
2003-09-04 |
Pfizer Inc. |
Nicotinamide derivatives useful as pde4 inhibitors
|
US6756392B2
(en)
|
2002-02-11 |
2004-06-29 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
TW200400055A
(en)
*
|
2002-02-22 |
2004-01-01 |
Pharmacia Corp |
Ophthalmic formulation with novel gum composition
|
BR0307898A
(en)
*
|
2002-02-22 |
2004-12-07 |
Pharmacia Corp |
Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
|
GB0207104D0
(en)
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
US6855724B2
(en)
|
2002-04-08 |
2005-02-15 |
Agouron Pharmaceuticals, Inc. |
Tropane derivatives useful in therapy
|
GB0209022D0
(en)
|
2002-04-19 |
2002-05-29 |
Imp College Innovations Ltd |
Compounds
|
US6869939B2
(en)
*
|
2002-05-04 |
2005-03-22 |
Cydex, Inc. |
Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
|
US6818662B2
(en)
*
|
2002-05-28 |
2004-11-16 |
Taisho Pharmaceutical Co., Ltd. |
Pharmaceutical composition
|
GB0212749D0
(en)
*
|
2002-06-01 |
2002-07-10 |
Boots Co Plc |
Personal care compositions
|
EP1542668B1
(en)
*
|
2002-08-20 |
2009-04-15 |
Bristol-Myers Squibb Company |
Aripiprazole complex formulation and method
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
PT2277551E
(en)
|
2002-09-06 |
2013-08-22 |
Cerulean Pharma Inc |
Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
|
GB0221169D0
(en)
|
2002-09-12 |
2002-10-23 |
Univ Bath |
Crystal
|
CA2498410A1
(en)
*
|
2002-09-13 |
2004-03-25 |
Cydex, Inc. |
Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
|
US20040058895A1
(en)
*
|
2002-09-18 |
2004-03-25 |
Bone Care International, Inc. |
Multi-use vessels for vitamin D formulations
|
US7148211B2
(en)
*
|
2002-09-18 |
2006-12-12 |
Genzyme Corporation |
Formulation for lipophilic agents
|
US7230025B2
(en)
|
2002-09-26 |
2007-06-12 |
Pfizer, Inc. |
Pyrazole derivatives
|
US6933312B2
(en)
|
2002-10-07 |
2005-08-23 |
Agouron Pharmaceuticals, Inc. |
Pyrazole derivatives
|
IL152575A
(en)
*
|
2002-10-31 |
2008-12-29 |
Transpharma Medical Ltd |
Transdermal delivery system for water insoluble drugs
|
IL152573A
(en)
*
|
2002-10-31 |
2009-11-18 |
Transpharma Medical Ltd |
Transdermal delivery system for anti-emetic medication
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
KR20070091049A
(en)
|
2002-12-13 |
2007-09-06 |
워너-램버트 캄파니 엘엘씨 |
Alpha-2-delta ligand to treat lower urinary tract symptoms
|
CA2451267A1
(en)
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
NZ541658A
(en)
*
|
2003-01-14 |
2008-04-30 |
Teva Pharma |
Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
|
UA83816C2
(en)
*
|
2003-01-14 |
2008-08-26 |
Тева Фармасьютикал Индастриз, Лтд |
Pharmaceutical composition comprising a peptide and substituted -cyclodextrin for the treatment of systemic lupus erythematosus
|
EP1460064A1
(en)
|
2003-03-14 |
2004-09-22 |
Pfizer Limited |
Indole-2-carboxamide derivatives useful as beta-2 agonists
|
EP2301549A1
(en)
*
|
2003-04-18 |
2011-03-30 |
Advanced Medicine Research Institute |
Remedies for diseases to be applied to eye
|
CL2004000826A1
(en)
|
2003-04-25 |
2005-03-04 |
Pfizer |
USE OF AN AGONIST FOR THE 5-HT2C RECEPTOR TO PREPARE A USEFUL MEDICINAL PRODUCT IN THE TREATMENT OF URINARY INCONTINENCE CAUSED BY STRESS, WITH THE CONDITION THAT THE AGONIST IS NOT 1- [6-CHLORINE-5- (TRIFLUOROMETIL) -2- PIRIDINIL] PIPERAZINA (ORG-129
|
US7157446B2
(en)
*
|
2003-05-02 |
2007-01-02 |
Bristol Myers Squibb Company |
Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
|
US7268147B2
(en)
|
2003-05-15 |
2007-09-11 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
DE602004024417D1
(en)
|
2003-09-03 |
2010-01-14 |
Glaxo Group Ltd |
NEW METHOD FOR THE PRODUCTION OF PLEUROMUTILINE DERIVATIVES
|
AU2004268840B9
(en)
|
2003-09-03 |
2011-02-03 |
Pfizer Inc. |
Benzimidazolone compounds having 5-HT4 receptor agonistic activity
|
US7220772B2
(en)
|
2003-09-05 |
2007-05-22 |
Pfizer, Inc. |
Pyrazole derivatives
|
US6960300B2
(en)
*
|
2003-09-08 |
2005-11-01 |
Sami Labs Limited |
Process for preparing water soluble diterpenes and their applications
|
CA2537402C
(en)
|
2003-09-12 |
2009-05-05 |
Pfizer Inc. |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
|
MXPA06003749A
(en)
|
2003-10-03 |
2006-06-14 |
Pfizer |
Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation.
|
NZ546106A
(en)
|
2003-10-10 |
2008-10-31 |
Antares Pharma Ipl Ag |
Transdermal pharmaceutical formulation for minimizing skin residues
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
US7129042B2
(en)
*
|
2003-11-03 |
2006-10-31 |
Diagnostic Hybrids, Inc. |
Compositions and methods for detecting severe acute respiratory syndrome coronavirus
|
ATE497763T1
(en)
|
2003-11-21 |
2011-02-15 |
Zalicus Inc |
METHODS AND REAGENTS FOR TREATING INFLAMMATORY DISEASES
|
AU2004312095A1
(en)
*
|
2003-12-31 |
2005-07-21 |
Cydex Pharmaceuticals, Inc. |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
|
US20070020196A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
|
US20070020299A1
(en)
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
PT1708991E
(en)
|
2004-01-22 |
2007-12-14 |
Pfizer |
Sulfonamide derivatives for the treatment of diseases
|
AU2005214154B2
(en)
|
2004-01-22 |
2008-01-24 |
Pfizer Inc. |
Sulfonamide derivatives for the treatment of diseases
|
US7629358B2
(en)
|
2004-03-17 |
2009-12-08 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
AU2005223483B2
(en)
|
2004-03-18 |
2009-04-23 |
Zoetis Llc |
N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
|
US7538141B2
(en)
|
2004-03-23 |
2009-05-26 |
Alan Daniel Brown |
Compounds for the treatment of diseases
|
EP1730103B1
(en)
|
2004-03-23 |
2010-05-26 |
Pfizer Limited |
Formamide derivatives useful as adrenoceptor
|
CN103554222A
(en)
*
|
2004-04-15 |
2014-02-05 |
欧尼斯治疗公司 |
Compounds for enzyme inhibition
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
US20050234018A1
(en)
*
|
2004-04-15 |
2005-10-20 |
Allergan, Inc. |
Drug delivery to the back of the eye
|
SI2708225T1
(en)
*
|
2004-04-23 |
2019-05-31 |
Cydex Pharmaceuticals, Inc. |
DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin
|
CA2564994A1
(en)
|
2004-04-30 |
2005-11-10 |
Warner-Lambert Company Llc |
Substituted morpholine compounds for the treatment of central nervous system disorders
|
US20050250738A1
(en)
*
|
2004-05-06 |
2005-11-10 |
Mosher Gerold L |
Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
|
US7456164B2
(en)
|
2004-05-07 |
2008-11-25 |
Pfizer, Inc |
3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
|
SI2030981T1
(en)
*
|
2004-05-10 |
2014-11-28 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
EP1595881A1
(en)
|
2004-05-12 |
2005-11-16 |
Pfizer Limited |
Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
|
US7737163B2
(en)
|
2004-06-15 |
2010-06-15 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
AU2005254800B2
(en)
|
2004-06-15 |
2010-12-09 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
SI1778686T1
(en)
|
2004-08-12 |
2009-02-28 |
Pfizer |
Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
|
PT1786785E
(en)
|
2004-08-26 |
2010-05-21 |
Pfizer |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
ITMI20041763A1
(en)
*
|
2004-09-16 |
2004-12-16 |
Altergon Sa |
NEW INJECTABLE FORMULATIONS CONTAINING PROGESTERONE
|
MX2007005290A
(en)
|
2004-11-02 |
2007-07-09 |
Pfizer |
Sulfonyl benzimidazole derivatives.
|
US9120774B2
(en)
|
2004-11-03 |
2015-09-01 |
University Of Kansas |
Novobiocin analogues having modified sugar moieties
|
GT200500317A
(en)
*
|
2004-11-05 |
2006-10-27 |
|
PROCESS TO PREPARE QUINOLINE COMPOUNDS AND PRODUCTS OBTAINED FROM THEM
|
US20060105045A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Buchanan Charles M |
Cyclodextrin solubilizers for liquid and semi-solid formulations
|
US20060105992A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Buchanan Charles M |
Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
|
EP1819353B1
(en)
*
|
2004-12-07 |
2011-02-23 |
Proteolix, Inc. |
Composition for proteasome inhibition
|
EP1674098A1
(en)
|
2004-12-23 |
2006-06-28 |
Schering Aktiengesellschaft |
Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
|
WO2006091885A2
(en)
|
2005-02-24 |
2006-08-31 |
Dr Pharma Nova, Llc |
A registry method and control system for dea schedule ii-v medicines
|
CA2601508C
(en)
|
2005-03-17 |
2012-01-03 |
Pfizer, Inc. |
Cyclopropanecarboxamide derivatives
|
ES2313626T3
(en)
|
2005-03-21 |
2009-03-01 |
Pfizer Limited |
TRIAZOL DERIVATIVES SUBSTITUTED AS AN OXITOCINE ANTAGONISTS.
|
US7745494B2
(en)
*
|
2005-04-15 |
2010-06-29 |
Albert Einstein College Of Medicine Of Yeshiva University |
Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy
|
DK1874331T3
(en)
|
2005-04-19 |
2014-12-01 |
King S College London |
APPLICATION OF BIP against bone loss and osteoporosis
|
GT200600162A
(en)
*
|
2005-04-24 |
2007-03-14 |
|
METHODS TO MODULATE THE FUNCTION OF THE BLADDER
|
CA2607780A1
(en)
|
2005-05-04 |
2006-11-09 |
Pfizer Limited |
Purine derivatives
|
ES2393768T3
(en)
|
2005-05-26 |
2012-12-27 |
Neuron Systems, Inc |
Quinoline derivative for the treatment of retinal diseases
|
US8067399B2
(en)
|
2005-05-27 |
2011-11-29 |
Antares Pharma Ipl Ag |
Method and apparatus for transdermal or transmucosal application of testosterone
|
JPWO2006134877A1
(en)
*
|
2005-06-13 |
2009-01-08 |
武田薬品工業株式会社 |
Injection
|
WO2006134468A1
(en)
|
2005-06-15 |
2006-12-21 |
Pfizer Limited |
Substituted arylpyrazoles for use against parasitites
|
US20080146643A1
(en)
*
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
US7645786B2
(en)
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
US20080176865A1
(en)
*
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
AR054849A1
(en)
*
|
2005-07-26 |
2007-07-18 |
Wyeth Corp |
DIAZEPINOQUINOLINAS, SYNTHESIS OF THE SAME, AND INTERMEDIARIES TO OBTAIN THEM
|
US20070191306A1
(en)
*
|
2005-08-17 |
2007-08-16 |
Bristol-Myers Squibb Company |
FACTOR Xa INHIBITOR FORMULATION AND METHOD
|
DE102005041860A1
(en)
*
|
2005-09-02 |
2007-03-08 |
Schering Ag |
Nano-particle embedded- and charged-complex, useful for the production of a pharmaceutical composition, comprises two complex partners, where the complex partner is an embedded anionic and a cationic active substance
|
MX2008004287A
(en)
|
2005-09-30 |
2008-10-23 |
Ovation Pharmaceuticals Inc |
Novel parenteral carbamazepine formulation.
|
US20100204178A1
(en)
*
|
2006-10-02 |
2010-08-12 |
James Cloyd |
Novel parenteral carbamazepine formulation
|
PL2335707T3
(en)
*
|
2005-10-26 |
2015-10-30 |
Cydex Pharmaceuticals Inc |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
US8716322B2
(en)
|
2005-11-09 |
2014-05-06 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
ES2812250T3
(en)
|
2005-11-28 |
2021-03-16 |
Marinus Pharmaceuticals Inc |
Ganaxolone formulations and procedures for their preparation and use
|
US20070135586A1
(en)
*
|
2005-12-09 |
2007-06-14 |
Shreyas Chakravarti |
Polyamide blend compositions formed article and process thereof
|
US20070197486A1
(en)
*
|
2005-12-20 |
2007-08-23 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids
|
JP2009520823A
(en)
*
|
2005-12-20 |
2009-05-28 |
ティカ レーケメデル アーベー |
Methods and systems for delivering corticosteroids with improved pharmacokinetic profiles
|
US20070160542A1
(en)
*
|
2005-12-20 |
2007-07-12 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
NL2000323C2
(en)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine derivatives.
|
US20070249572A1
(en)
*
|
2005-12-20 |
2007-10-25 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070178049A1
(en)
*
|
2005-12-20 |
2007-08-02 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070185066A1
(en)
*
|
2005-12-20 |
2007-08-09 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070141684A1
(en)
|
2005-12-21 |
2007-06-21 |
Pfizer Inc |
Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
|
GB0600406D0
(en)
|
2006-01-10 |
2006-02-15 |
Univ Bath |
Crystal
|
TW200734334A
(en)
*
|
2006-01-13 |
2007-09-16 |
Wyeth Corp |
Treatment of substance abuse
|
GB0600928D0
(en)
|
2006-01-17 |
2006-02-22 |
Novacta Biosystems Ltd |
Improvements relating to lantibiotics
|
WO2007095341A2
(en)
*
|
2006-02-15 |
2007-08-23 |
Tika Läkemedel Ab |
Sterilization of corticosteroids with reduced mass loss
|
US20070225274A1
(en)
*
|
2006-03-24 |
2007-09-27 |
Wyeth |
Methods for modulating bladder function
|
CL2007000773A1
(en)
*
|
2006-03-24 |
2008-01-25 |
Wyeth Corp |
Use of compounds derived from condensed diazepine for the treatment of a cognitive disorder such as add or adhd; or its use to treat spm or pmdd.
|
AU2007231011A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
New therapeutic combinations for the treatment of depression
|
PE20081192A1
(en)
*
|
2006-03-24 |
2008-10-07 |
Wyeth Corp |
PAIN TREATMENT
|
CL2007000775A1
(en)
*
|
2006-03-24 |
2008-01-25 |
Wyeth Corp |
Use of benzofuran-derived compounds for the treatment of a cognitive disorder.
|
US20070238789A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Chin-Ming Chang |
Prednisolone acetate compositions
|
BRPI0710287A2
(en)
*
|
2006-04-18 |
2012-05-29 |
Ekr Therapeutics Inc |
pharmaceutical composition, method for treating an individual for high blood pressure, inclusion complex, and methods for treating and preventing acute elevations of blood pressure in a human individual and for inducing hypotension in a human individual.
|
CA2646667C
(en)
|
2006-04-21 |
2014-03-11 |
Antares Pharma Ipl Ag |
Methods of treating hot flashes with formulations for transdermal or transmucosal application
|
CN100374468C
(en)
*
|
2006-05-25 |
2008-03-12 |
重庆通量精细化工有限公司 |
Synthetic process for water soluble sulfoalkyl ether-beta-cyclic dextrine
|
AU2007261345B2
(en)
|
2006-06-19 |
2012-02-23 |
Onyx Therapeutics, Inc. |
Peptide epoxyketones for proteasome inhibition
|
WO2008003317A1
(en)
*
|
2006-07-03 |
2008-01-10 |
Genmab A/S |
Prevention of rash in patients undergoing anti-egfr therapy
|
AR061889A1
(en)
|
2006-07-13 |
2008-10-01 |
Medichem Sa |
IMPROVED PROCESS FOR THE PREPARATION OF VORICONAZOL
|
WO2008012538A2
(en)
|
2006-07-25 |
2008-01-31 |
The Secretary Of State For Defence |
Live vaccine strains of francisella
|
US20100022481A1
(en)
*
|
2006-08-02 |
2010-01-28 |
Dong Wang |
Drug Carriers, Their Synthesis, and Methods of Use Thereof
|
US20080207731A1
(en)
|
2006-08-23 |
2008-08-28 |
Intellect Neurosciences, Inc. |
3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
|
US20100093861A1
(en)
|
2006-09-15 |
2010-04-15 |
Stevia Aps |
Treatment of insulin resistance or diseases associated with insulin resistance
|
US20090239942A1
(en)
*
|
2006-09-15 |
2009-09-24 |
Cloyd James C |
Topiramate Compositions and Methods of Making and Using the Same
|
EP2061458B1
(en)
*
|
2006-09-15 |
2014-12-10 |
Regents of the University of Minnesota |
Topiramate compositions and methods for their use
|
CA2657550C
(en)
|
2006-09-21 |
2011-11-01 |
Raqualia Pharma Inc. |
Benzimidazole derivatives as selective acid pump inhibitors
|
JP2010506839A
(en)
|
2006-10-12 |
2010-03-04 |
ワイス エルエルシー |
Methods and compositions with reduced opalescence
|
MX2009004233A
(en)
|
2006-10-18 |
2009-08-12 |
Pfizer Prod Inc |
Biaryl ether urea compounds.
|
US8455471B2
(en)
|
2006-10-20 |
2013-06-04 |
Icos Corporation |
Compositions of CHK1 inhibitors and cyclodextrin
|
WO2008050199A2
(en)
|
2006-10-23 |
2008-05-02 |
Pfizer Japan Inc. |
Substituted phenylmethyl bicyclocarboxyamide compounds
|
US8158609B1
(en)
*
|
2006-11-02 |
2012-04-17 |
Novartis Ag |
Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
|
JP5401319B2
(en)
|
2006-11-03 |
2014-01-29 |
ワイス・エルエルシー |
Glycolytic inhibitors in cell culture
|
KR100822133B1
(en)
*
|
2006-11-06 |
2008-04-15 |
한미약품 주식회사 |
Complex formulation for preventing or treating osteoporosis which comprises solid dispersion of vitamin d or its derivative and bisphosphonate
|
US20100056500A1
(en)
*
|
2006-11-21 |
2010-03-04 |
Thitiwan Buranachokaisan |
Stable Parenteral Formulation
|
JP2010516625A
(en)
|
2007-01-24 |
2010-05-20 |
インサート セラピューティクス, インコーポレイテッド |
Polymer-drug conjugates with tether groups for controlled drug delivery
|
DK2115126T3
(en)
|
2007-03-02 |
2015-05-04 |
Wyeth Llc |
Use of copper and glutamate in cell culture for the preparation of polypeptides
|
CN101657203B
(en)
*
|
2007-03-02 |
2012-09-05 |
卧龙岗大学 |
Compositions and methods for delivery of anti-cancer agents
|
AU2015255164B2
(en)
*
|
2007-04-27 |
2017-06-08 |
Cydex Pharmaceuticals, Inc. |
Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
|
WO2008134600A1
(en)
*
|
2007-04-27 |
2008-11-06 |
Cydex Pharmaceuticals, Inc. |
Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
|
US7960353B2
(en)
*
|
2007-05-10 |
2011-06-14 |
University Of Kansas |
Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
|
JP2010527986A
(en)
*
|
2007-05-24 |
2010-08-19 |
ファイザー・リミテッド |
Spirocyclic quinazoline derivatives and their use as PDE7 inhibitors
|
WO2008147556A2
(en)
|
2007-05-25 |
2008-12-04 |
Ipsen Pharma S.A.S. |
Melanocortin receptor ligands modified with hydantoin
|
ES2493641T3
(en)
*
|
2007-06-28 |
2014-09-12 |
Cydex Pharmaceuticals, Inc. |
Nasal administration of aqueous corticosteroid solutions
|
TWI428132B
(en)
|
2007-07-02 |
2014-03-01 |
Lilly Co Eli |
Potentiation of cancer chemotherapy
|
GB0714030D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
The use of type-B lantibiotic-based compounds having antimicrobial activity
|
GB0714029D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
Lantibiotic-based compounds having antimicrobial activity
|
KR100929920B1
(en)
|
2007-09-05 |
2009-12-04 |
주식회사 마크로케어 |
Method for preparing clathrate containing hydrophobic physiologically active ingredient in cyclodextrin and derivatives thereof and use of clathrate prepared thereby
|
EP2215087B1
(en)
|
2007-09-05 |
2013-12-18 |
Rigel Pharmaceuticals, Inc. |
Xinafoate salt of n4- (2,2-difluoro-4h-benzo [1,4] oxazin-3-one) - 6-yl] - 5-fluoro-n2 - [3-(methylaminocarbonylmethyleneoxy) phenyl] 2,4-pyrimidinediamine
|
CL2008002777A1
(en)
*
|
2007-09-21 |
2010-01-22 |
Wyeth Corp |
Method of preparing chiral diazepinoquinoline compounds by recrystallization in a ternary solvent system.
|
ME02462B
(en)
*
|
2007-10-04 |
2017-02-20 |
Onyx Therapeutics Inc |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
EP2057982A1
(en)
*
|
2007-11-09 |
2009-05-13 |
Archimedes Development Limited |
Intranasal compositions
|
US7999741B2
(en)
*
|
2007-12-04 |
2011-08-16 |
Avaya Inc. |
Systems and methods for facilitating a first response mission at an incident scene using precision location
|
US8192721B2
(en)
*
|
2007-12-13 |
2012-06-05 |
Verrow Pharmaceuticals, Inc. |
Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
|
US8815953B2
(en)
*
|
2008-03-13 |
2014-08-26 |
Spectrum Pharmaceuticals, Inc. |
Formulations of vitamin K analogs for topical use
|
GB2458473A
(en)
|
2008-03-17 |
2009-09-23 |
Imuthes Ltd |
3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
|
US7635773B2
(en)
|
2008-04-28 |
2009-12-22 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions
|
US20110224232A1
(en)
*
|
2008-05-06 |
2011-09-15 |
Board Of Regents, The University Of Texas System |
Treatment of Pulmonary Fungal Infection With Voriconazole via Inhalation
|
EP2303229A1
(en)
*
|
2008-06-16 |
2011-04-06 |
Debiopharm S.A. |
Concentrated oxaliplatin solution and its method of preparation
|
US20100022635A1
(en)
*
|
2008-07-28 |
2010-01-28 |
University Of Kansas |
Heat shock protein 90 inhibitor dosing methods
|
EP2328890B1
(en)
|
2008-08-06 |
2012-01-25 |
Pfizer Inc. |
6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
|
EP2163253B1
(en)
|
2008-09-15 |
2013-07-17 |
ULLRICH, Oliver |
Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof
|
US20100093872A1
(en)
*
|
2008-10-15 |
2010-04-15 |
Erimos Pharmaceuticals Llc |
Stable aqueous formulations of water insoluble or poorly soluble drugs
|
JP5675629B2
(en)
|
2008-10-21 |
2015-02-25 |
オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. |
Combination therapy using peptide epoxyketone
|
WO2010053487A1
(en)
|
2008-11-07 |
2010-05-14 |
Cydex Pharmaceuticals, Inc. |
Composition containing sulfoalkyl ether cyclodextrin and latanoprost
|
PE20160116A1
(en)
|
2008-11-15 |
2016-03-09 |
Melinta Therapeutics Inc |
ANTIMICROBIAL COMPOSITIONS
|
MX2011005221A
(en)
|
2008-11-21 |
2011-08-03 |
Raqualia Pharma Inc |
Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity.
|
WO2010080528A1
(en)
|
2008-12-17 |
2010-07-15 |
Genentech, Inc. |
Hepatitis c virus combination therapy
|
WO2010079443A1
(en)
|
2009-01-12 |
2010-07-15 |
Pfizer Limited |
Sulfonamide derivatives
|
GB0900599D0
(en)
|
2009-01-14 |
2009-02-18 |
Novacta Biosystems Ltd |
Treatment
|
TWI453029B
(en)
|
2009-01-14 |
2014-09-21 |
Novacta Biosystems Ltd |
Deoxyactagardine b, pharmaceutical composition comprising the same and method for preparing it
|
CN102388060B
(en)
|
2009-02-04 |
2014-09-10 |
诺瓦克塔生物系统有限公司 |
Actagardine derivatives
|
WO2010103070A2
(en)
|
2009-03-12 |
2010-09-16 |
Charité - Universitätsmedizin Berlin |
Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
|
TWI504598B
(en)
|
2009-03-20 |
2015-10-21 |
Onyx Therapeutics Inc |
Crystalline tripeptide epoxy ketone protease inhibitors
|
EP2233502A1
(en)
|
2009-03-27 |
2010-09-29 |
Deutsches Rheuma-Forschungszentrum Berlin |
Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
|
WO2010116270A1
(en)
|
2009-04-10 |
2010-10-14 |
Pfizer Inc. |
Ep2/4 agonists
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
KR20190071006A
(en)
|
2009-05-13 |
2019-06-21 |
사이덱스 파마슈티칼스, 인크. |
Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
|
CA2763365C
(en)
|
2009-05-29 |
2016-09-13 |
Cydex Pharmaceuticals, Inc. |
Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
|
US11020363B2
(en)
|
2009-05-29 |
2021-06-01 |
Cydex Pharmaceuticals, Inc. |
Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
|
CA2760284A1
(en)
|
2009-05-29 |
2010-12-02 |
Pfizer Limited |
Novel glucocorticoid receptor agonists
|
US8492538B1
(en)
|
2009-06-04 |
2013-07-23 |
Jose R. Matos |
Cyclodextrin derivative salts
|
EP2266563A1
(en)
|
2009-06-11 |
2010-12-29 |
Charité-Universitätsmedizin Berlin (Charité) |
Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
|
EP2442791B1
(en)
|
2009-06-16 |
2019-11-27 |
Pfizer Inc. |
Dosage forms of apixaban
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
DE102009034368A1
(en)
|
2009-07-20 |
2011-01-27 |
Bayer Schering Pharma Aktiengesellschaft |
17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-acyloxyalkylenephenyl derivatives, process for their preparation and their use for the treatment of diseases
|
WO2011041593A1
(en)
*
|
2009-09-30 |
2011-04-07 |
University Of Kansas |
Novobiocin analogues and treatment of polycystic kidney disease
|
WO2011060179A1
(en)
|
2009-11-13 |
2011-05-19 |
Onyx Therapeutics, Inc |
Use of peptide epoxyketones for metastasis suppression
|
WO2011077313A1
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Inc. |
Piperidinecarboxamides as mpges - 1 inhibitors
|
NZ601267A
(en)
|
2009-12-23 |
2014-03-28 |
Takeda Pharmaceutical |
Fused heteroaromatic pyrrolidinones as syk inhibitors
|
WO2011083387A1
(en)
|
2010-01-07 |
2011-07-14 |
Pfizer Limited |
Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
|
SI2525798T1
(en)
|
2010-01-21 |
2018-01-31 |
Drawbridge Pharmaceuticals Pty Ltd. |
Anaesthetic formulation
|
GB201001688D0
(en)
|
2010-02-02 |
2010-03-17 |
Novacta Biosystems Ltd |
Compounds
|
US20120309676A1
(en)
|
2010-02-02 |
2012-12-06 |
Sjoerd Nicolaas Wadman |
Lantibiotic Salts
|
EP2539358A1
(en)
|
2010-02-25 |
2013-01-02 |
Pfizer Limited |
Peptide analogues
|
KR20130075723A
(en)
|
2010-03-01 |
2013-07-05 |
오닉스 세라퓨틱스, 인크. |
Compounds for immunoproteasome inhibition
|
AU2011228758A1
(en)
*
|
2010-03-13 |
2012-11-08 |
Eastpond Laboratories Limited |
Fat-binding compositions
|
KR20130094185A
(en)
|
2010-04-07 |
2013-08-23 |
오닉스 세라퓨틱스, 인크. |
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
US8916593B2
(en)
|
2010-05-04 |
2014-12-23 |
Pfizer Inc. |
Alkoxy-substituted 2-aminopyridines as ALK inhibitors
|
WO2011149349A1
(en)
|
2010-05-26 |
2011-12-01 |
Neurophyxia B.V. |
2-iminobiotin formulations and uses thereof
|
WO2011154871A1
(en)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
EP2579869A2
(en)
*
|
2010-06-11 |
2013-04-17 |
Baxter International Inc |
Formulations including amiodarone and salts thereof and methods of their manufacture and use
|
CA2804593C
(en)
|
2010-07-09 |
2015-11-24 |
Pfizer Limited |
Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
|
US9145407B2
(en)
|
2010-07-09 |
2015-09-29 |
Pfizer Limited |
Sulfonamide compounds
|
US9096558B2
(en)
|
2010-07-09 |
2015-08-04 |
Pfizer Limited |
N-sulfonylbenzamide compounds
|
US9096500B2
(en)
|
2010-07-12 |
2015-08-04 |
Pfizer Limited |
Acyl sulfonamide compounds
|
EP2593427B1
(en)
|
2010-07-12 |
2014-12-24 |
Pfizer Limited |
Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
|
US8772343B2
(en)
|
2010-07-12 |
2014-07-08 |
Pfizer Limited |
Chemical compounds
|
CA2801032A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
|
US9102621B2
(en)
|
2010-07-12 |
2015-08-11 |
Pfizer Limited |
Acyl sulfonamide compounds
|
GB201013507D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013513D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Formulations
|
GB201013509D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013508D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
CN103154012B
(en)
|
2010-08-24 |
2015-11-25 |
英皇创新有限公司 |
The sugared dendrimer of poly-propyl ether imines
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
WO2012061413A2
(en)
|
2010-11-01 |
2012-05-10 |
Marshall Edwards, Inc. |
Isoflavonoid compositions and methods for the treatment of cancer
|
EP2640729B1
(en)
|
2010-11-15 |
2016-12-21 |
VIIV Healthcare UK Limited |
Inhibitors of hiv replication
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
KR101914940B1
(en)
|
2011-01-26 |
2018-11-06 |
알러간, 인코포레이티드 |
Androgen composition for treating an opthalmic condition
|
US8791107B2
(en)
|
2011-02-25 |
2014-07-29 |
Takeda Pharmaceutical Company Limited |
N-substituted oxazinopteridines and oxazinopteridinones
|
WO2012120398A1
(en)
|
2011-03-04 |
2012-09-13 |
Pfizer Limited |
Aryl substituted carboxamide derivatives as trpm8 modulators
|
MA35024B1
(en)
|
2011-04-05 |
2014-04-03 |
Pfizer Ltd |
PYRROLO- [2,3-D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN-RELATED KINASES
|
WO2012157288A1
(en)
|
2011-05-18 |
2012-11-22 |
Raqualia Pharma Inc. |
Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
|
TWI544922B
(en)
|
2011-05-19 |
2016-08-11 |
愛爾康研究有限公司 |
High concentration olopatadine ophthalmic composition
|
KR101731155B1
(en)
|
2011-06-15 |
2017-04-27 |
신톤 비.브이. |
Stabilized voriconazole composition
|
WO2012177714A1
(en)
|
2011-06-22 |
2012-12-27 |
Takeda Pharmaceutical Company Limited |
Substituted 6-aza-isoindolin-1-one derivatives
|
EP2731959B1
(en)
|
2011-07-13 |
2016-02-03 |
Pfizer Limited |
Enkephalin analogues
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
WO2013017136A1
(en)
|
2011-08-02 |
2013-02-07 |
Pensieve Biosciences Cyprus Limited |
Treatment of cognitive impairment
|
US20160206608A1
(en)
|
2011-08-02 |
2016-07-21 |
Pfizer Inc. |
Crizotinib for use in the treatment of cancer
|
DK2753632T3
(en)
|
2011-09-08 |
2023-07-10 |
Sage Therapeutics Inc |
NEUROACTIVE STEROIDS, COMPOSITIONS AND USE THEREOF
|
EP3318284B1
(en)
|
2011-09-18 |
2022-01-26 |
Euro-Celtique S.A. |
Pharmaceutical composition comprising an hdac inhibitor and a cyclopolysaccharide
|
WO2013054185A1
(en)
|
2011-10-13 |
2013-04-18 |
Pfizer, Inc. |
Pyrimidine and pyridine derivatives useful in therapy
|
EP3572417A3
(en)
|
2011-10-14 |
2020-03-25 |
Sage Therapeutics, Inc. |
3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
|
JP5363636B2
(en)
|
2011-10-21 |
2013-12-11 |
ファイザー・リミテッド |
New salts and medical uses
|
WO2013061205A2
(en)
|
2011-10-26 |
2013-05-02 |
Pfizer Limited |
Chemical compounds
|
CN103958481B
(en)
|
2011-10-28 |
2017-06-30 |
因西必泰克新有限公司 |
Can be used for the pyridyl derivatives treated
|
EP2791108B1
(en)
|
2011-12-15 |
2016-07-27 |
Pfizer Limited |
Sulfonamide derivatives
|
WO2013093688A1
(en)
|
2011-12-19 |
2013-06-27 |
Pfizer Limited |
Sulfonamide derivatives and use thereof as vgsc inhibitors
|
TW201332572A
(en)
|
2011-12-28 |
2013-08-16 |
Otsuka Pharma Co Ltd |
Pharmaceutical preparation comprising substituted β -cyclodextrin
|
EP2800740A1
(en)
|
2012-01-04 |
2014-11-12 |
Pfizer Limited |
N-aminosulfonyl benzamides
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
TWI573792B
(en)
|
2012-02-01 |
2017-03-11 |
歐陸斯迪公司 |
Novel therapeutic agents
|
ES2548228T3
(en)
|
2012-02-03 |
2015-10-15 |
Pfizer Inc |
Benzimidazole and imidazopyridine derivatives as sodium channel modulators
|
TW201336527A
(en)
|
2012-02-10 |
2013-09-16 |
Alcon Res Ltd |
Aqueous pharmaceutical composition with enhanced stability
|
CN104271605B
(en)
|
2012-02-15 |
2017-07-25 |
锡德克斯药物公司 |
The manufacture method of cyclodextrine derivatives
|
RU2747757C2
(en)
|
2012-02-28 |
2021-05-13 |
Сидекс Фармасьютикалс, Инк. |
Compositions of alkylated cyclodextrin and methods of their preparation and application
|
AU2013229173B2
(en)
|
2012-03-06 |
2017-06-01 |
Pfizer Inc. |
Macrocyclic derivatives for the treatment of proliferative diseases
|
US9365566B2
(en)
|
2012-03-27 |
2016-06-14 |
Takeda Pharmaceutical Company Limited |
Cinnoline derivatives
|
CN104302673B
(en)
|
2012-03-30 |
2017-09-22 |
赛博尔泰克股份公司 |
Anthocyanidin compound
|
WO2014011695A2
(en)
|
2012-07-09 |
2014-01-16 |
Onyx Therapeutics, Inc. |
Prodrugs of peptide epoxy ketone protease inhibitors
|
UY34893A
(en)
|
2012-07-10 |
2014-02-28 |
Takeda Pharmaceutical |
DERIVATIVES OF AZAINDOL
|
JP2015524444A
(en)
|
2012-08-03 |
2015-08-24 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Cyclodextrins for the treatment of lysosomal storage diseases
|
US9475816B2
(en)
|
2012-09-07 |
2016-10-25 |
Takeda Pharmaceutical Company Limited |
Substituted-1,4-dihydropyrazolo[4,3-b]indoles
|
WO2014045029A1
(en)
|
2012-09-18 |
2014-03-27 |
Ziarco Pharma Ltd |
2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
|
JP6254169B2
(en)
|
2012-09-28 |
2017-12-27 |
ファイザー・インク |
Benzamide and heterobenzamide compounds
|
US20140094432A1
(en)
|
2012-10-02 |
2014-04-03 |
Cerulean Pharma Inc. |
Methods and systems for polymer precipitation and generation of particles
|
JP2015531394A
(en)
|
2012-10-04 |
2015-11-02 |
ファイザー・リミテッドPfizer Limited |
Pyrrolo [2,3-D] pyrimidine tropomyosin-related kinase inhibitor
|
EP2912036A1
(en)
|
2012-10-04 |
2015-09-02 |
Pfizer Limited |
Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
|
CA2885247A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Tropomyosin-related kinase inhibitors
|
US20150258202A1
(en)
*
|
2012-10-17 |
2015-09-17 |
Sapiotec Gmbh |
Anthocyanidin complex for the treatment of multiple myeloma
|
MY181829A
(en)
|
2012-10-22 |
2021-01-08 |
Cydex Pharmaceuticals Inc |
Alkylated cyclodextrin compositions and processes for preparing and using the same
|
AU2013343105B2
(en)
|
2012-11-08 |
2016-04-14 |
Pfizer Inc. |
Heteroaromatic compounds as dopamine D1 ligands
|
CN104981472A
(en)
|
2012-11-08 |
2015-10-14 |
辉瑞大药厂 |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
DK2919791T3
(en)
*
|
2012-11-15 |
2017-07-17 |
Sapiotec Gmbh |
Delphinidine complex as antiflogistic or immunosuppressant active substance
|
CA2890861C
(en)
|
2012-11-21 |
2021-03-30 |
Raqualia Pharma Inc. |
Polymorphic forms of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
|
EP2925725B1
(en)
|
2012-12-03 |
2016-11-09 |
Pfizer Inc. |
Novel selective androgen receptor modulators
|
CA2893881C
(en)
*
|
2012-12-11 |
2020-09-22 |
Sapiotec Gmbh |
Delphinidin for combating melanoma cells
|
UA112028C2
(en)
|
2012-12-14 |
2016-07-11 |
Пфайзер Лімітед |
IMIDAZOPYRIDASINE DERIVATIVES AS HAMBA-RECEPTOR MODULATORS
|
UA111305C2
(en)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Condensed with lactams of aryl and heteroaryl
|
CA2898631C
(en)
|
2013-01-23 |
2023-06-13 |
Aldeyra Therapeutics, Inc. |
Toxic aldehyde related diseases and treatment
|
EP3431475B1
(en)
|
2013-02-21 |
2021-04-07 |
Pfizer Inc |
Solid forms of a selective cdk4/6 inhibitor
|
JO3377B1
(en)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
Pyridinyl and fused pyridinyl triazolone derivatives
|
PL2968369T3
(en)
|
2013-03-13 |
2019-03-29 |
Sage Therapeutics, Inc. |
Neuroactive steroids and methods of use thereof
|
EP2970504A4
(en)
|
2013-03-13 |
2017-01-18 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
EP2784083A1
(en)
|
2013-03-28 |
2014-10-01 |
Charité - Universitätsmedizin Berlin |
Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
|
PL2986623T3
(en)
|
2013-04-17 |
2019-04-30 |
Sage Therapeutics Inc |
19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
|
AU2014256228C1
(en)
|
2013-04-17 |
2017-09-14 |
Sage Therapeutics, Inc. |
19-nor neuroactive steroids and methods of use thereof
|
EP2792360A1
(en)
|
2013-04-18 |
2014-10-22 |
IP Gesellschaft für Management mbH |
(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
|
TW201443025A
(en)
|
2013-04-19 |
2014-11-16 |
Pfizer Ltd |
Chemical compounds
|
TW201512171A
(en)
|
2013-04-19 |
2015-04-01 |
Pfizer Ltd |
Chemical compounds
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
MA38661A1
(en)
|
2013-06-27 |
2017-03-31 |
Pfizer |
Heteroaromatic compounds and their use as d1 dopamine ligands
|
US9364458B2
(en)
|
2013-07-08 |
2016-06-14 |
Abbvie Inc. |
Stabilized pharmaceutical dosage forms comprising atrasentan
|
GB201312737D0
(en)
|
2013-07-17 |
2013-08-28 |
Univ Greenwich |
Cyclodextrin
|
EP3868382A1
(en)
|
2013-07-19 |
2021-08-25 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
PT3488852T
(en)
|
2013-08-23 |
2021-02-03 |
Sage Therapeutics Inc |
Neuroactive steroids, compositions, and uses thereof
|
US8962675B1
(en)
|
2013-09-12 |
2015-02-24 |
Abbvie Inc. |
Atrasentan mandelate salts
|
CN104513253A
(en)
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
Macrocyclic compounds for the treatment of proliferative diseases
|
RU2572334C2
(en)
*
|
2013-12-06 |
2016-01-10 |
Общество С Ограниченной Ответственностью "Луфатен" |
Clathrate complex of arabinogalactan or arabic gum with 20-hydroxyecdysones, method for producing it (versions), pharmaceutical composition and medicinal product
|
CA2934010A1
(en)
|
2013-12-20 |
2015-06-25 |
Pfizer Limited |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
UY35945A
(en)
|
2014-01-09 |
2015-08-31 |
Takeda Pharmaceutical |
DERIVATIVES OF AZAINDOL
|
WO2015106014A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
CN104971355B
(en)
*
|
2014-04-02 |
2018-04-24 |
上海现代药物制剂工程研究中心有限公司 |
Composition containing razaxaban and preparation method thereof
|
WO2015159175A1
(en)
|
2014-04-15 |
2015-10-22 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
|
TN2016000452A1
(en)
|
2014-04-25 |
2018-04-04 |
Pfizer |
Heteroaromatic compounds and their use as dopamine d1 ligands.
|
US9868744B2
(en)
|
2014-04-25 |
2018-01-16 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine D1 ligands
|
EP3134404A1
(en)
|
2014-04-25 |
2017-03-01 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
JP6564394B2
(en)
|
2014-04-28 |
2019-08-21 |
ファイザー・インク |
Heterocyclic compounds and their use as dopamine D1 ligands
|
EP3137454A1
(en)
|
2014-04-28 |
2017-03-08 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
EP3140298A1
(en)
|
2014-05-07 |
2017-03-15 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors
|
GEP20186921B
(en)
|
2014-05-14 |
2018-11-12 |
Pfizer |
Pyrazolopyridines and pyrazolopyrimidines
|
HUE052692T2
(en)
|
2014-05-15 |
2021-05-28 |
Pfizer |
Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
|
KR102471082B1
(en)
|
2014-05-20 |
2022-11-25 |
라퀄리아 파마 인코포레이티드 |
Benzisoxazole derivative salt
|
GB201409471D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409485D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409488D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
SI3705488T1
(en)
|
2014-05-29 |
2022-10-28 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions and uses thereof
|
EP3148992A1
(en)
|
2014-05-30 |
2017-04-05 |
Pfizer Inc. |
Benzenesulfonamides useful as sodium channel inhibitors
|
CA2950390C
(en)
|
2014-05-30 |
2020-09-22 |
Pfizer Inc. |
Carbonitrile derivatives as selective androgen receptor modulators
|
ES2664810T3
(en)
|
2014-06-12 |
2018-04-23 |
Pfizer Limited |
Imidazopyridazine derivatives as modulators of GABAA receptor activity
|
WO2015193768A1
(en)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Aryl fused lactams as ezh2 modulators
|
LT3157915T
(en)
|
2014-06-17 |
2019-04-25 |
Pfizer Inc. |
Substituted dihydroisoquinolinone compounds
|
EP3157528B1
(en)
|
2014-06-18 |
2023-09-13 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
WO2015195448A1
(en)
|
2014-06-18 |
2015-12-23 |
Eli Lilly And Company |
Transdermal formulations of pergolide and uses thereof
|
WO2016009296A1
(en)
|
2014-07-16 |
2016-01-21 |
Pfizer Inc. |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2016009303A1
(en)
|
2014-07-17 |
2016-01-21 |
Pfizer Inc. |
Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
|
WO2016009297A1
(en)
|
2014-07-18 |
2016-01-21 |
Pfizer Inc. |
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
|
WO2016020784A1
(en)
|
2014-08-05 |
2016-02-11 |
Pfizer Inc. |
N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
|
JP6914188B2
(en)
*
|
2014-08-22 |
2021-08-04 |
サイデックス・ファーマシューティカルズ・インコーポレイテッド |
Fractional Alkylated Cyclodextrin Composition and Method for Preparation and Use thereof
|
WO2016034971A1
(en)
|
2014-09-04 |
2016-03-10 |
Pfizer Limited |
Sulfonamides derivatives as urat1 inhibitors
|
JOP20200195A1
(en)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
Neuroactive steroids, compositions, and uses thereof
|
WO2016044433A2
(en)
|
2014-09-16 |
2016-03-24 |
Biopharma Works |
Metformin derivatives
|
GB201417163D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
|
GB201417165D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Treatments for Autoimmune Disease
|
PE20170907A1
(en)
|
2014-10-07 |
2017-07-12 |
Sage Therapeutics Inc |
NEUROACTIVE COMPOUNDS AND METHODS OF USING THEM
|
SG10202009859YA
(en)
|
2014-10-16 |
2020-11-27 |
Sage Therapeutics Inc |
Compositions and methods for treating cns disorders
|
NZ769042A
(en)
|
2014-10-16 |
2023-12-22 |
Sage Therapeutics Inc |
Compositions and methods for treating cns disorders
|
WO2016067143A1
(en)
|
2014-10-28 |
2016-05-06 |
Pfizer Inc. |
N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
|
LT3224269T
(en)
|
2014-11-27 |
2020-07-10 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
ES2746839T3
(en)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Pyrimidine and triazine derivatives and their use as AXL inhibitors
|
TW201636342A
(en)
|
2014-12-19 |
2016-10-16 |
武田藥品工業有限公司 |
Fumagillol derivatives
|
JP6342587B2
(en)
|
2015-01-22 |
2018-06-13 |
フィトプラント リサーチ エス.エル. |
Cannabinoid purification method, composition and kit
|
ES2764840T3
(en)
|
2015-01-28 |
2020-06-04 |
Univ Bordeaux |
Use of plerixafor to treat and / or prevent acute exacerbations of chronic obstructive pulmonary disease
|
CN116139125A
(en)
|
2015-02-02 |
2023-05-23 |
梅制药公司 |
Combination therapy
|
US20160228454A1
(en)
|
2015-02-06 |
2016-08-11 |
Marinus Pharmaceuticals, Inc. |
Intravenous ganaxolone formulations and methods of use in treating status epilepticus and other seizure disorders
|
ES2935476T3
(en)
|
2015-02-20 |
2023-03-07 |
Sage Therapeutics Inc |
Neuroactive steroids, compositions and uses thereof
|
CN107278205A
(en)
|
2015-02-24 |
2017-10-20 |
辉瑞大药厂 |
Substituted nucleoside derivates as anticarcinogen
|
JP6676650B2
(en)
|
2015-03-13 |
2020-04-08 |
エンドサイト・インコーポレイテッドEndocyte, Inc. |
Conjugates for treating diseases
|
MX2017011966A
(en)
|
2015-03-19 |
2018-06-06 |
Cydex Pharmaceuticals Inc |
Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same.
|
WO2016164763A1
(en)
|
2015-04-10 |
2016-10-13 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
BR112017026287A2
(en)
|
2015-06-10 |
2018-09-18 |
Vtesse Inc |
hydroxypropyl beta-cyclodextrin compositions and methods
|
EP3319610A4
(en)
|
2015-07-06 |
2019-03-06 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
IL305404A
(en)
|
2015-07-06 |
2023-10-01 |
Sage Therapeutics Inc |
Oxysterols and methods of use thereof
|
RS62220B1
(en)
|
2015-07-06 |
2021-09-30 |
Sage Therapeutics Inc |
Oxysterols and methods of use thereof
|
US20170007617A1
(en)
|
2015-07-09 |
2017-01-12 |
Gilead Sciences Drive |
Intravenous formulations of a late sodium current inhibitor
|
CN107849017B
(en)
|
2015-07-31 |
2021-03-30 |
辉瑞公司 |
1,1, 1-trifluoro-3-hydroxypropan-2-ylcarbamate derivatives and 1,1, 1-trifluoro-4-hydroxybutyl-2-ylcarbamate derivatives as MAGL inhibitors
|
WO2017035077A1
(en)
|
2015-08-21 |
2017-03-02 |
Aldeyra Therapeutics, Inc. |
Deuterated compounds and uses thereof
|
JP2018536677A
(en)
|
2015-12-10 |
2018-12-13 |
ファイザー・リミテッドPfizer Limited |
4- (Bifen-3-yl) -1H-pyrazolo [3,4-c] pyridazine derivatives of formula (I) as GABA receptor modulators for use in the treatment of epilepsy and pain
|
ES2877089T3
(en)
|
2015-12-24 |
2021-11-16 |
Takeda Pharmaceuticals Co |
Co-crystal, method of production thereof, and medicine containing said co-crystal
|
TWI726968B
(en)
|
2016-01-07 |
2021-05-11 |
開曼群島商Cs醫藥技術公司 |
Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
|
WO2017119732A1
(en)
|
2016-01-08 |
2017-07-13 |
Samsung Electronics Co., Ltd. |
Electronic device and operating method thereof
|
AU2017208119B2
(en)
|
2016-01-15 |
2019-11-07 |
Pfizer Inc. |
6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands
|
MX2018009948A
(en)
|
2016-02-18 |
2018-12-06 |
Melinta Therapeutics Inc |
Oritavancin formulations.
|
CN109069530A
(en)
|
2016-02-28 |
2018-12-21 |
奥尔德拉医疗公司 |
Allergic eye symptom is treated with cyclodextrin
|
EP3426772A4
(en)
|
2016-03-09 |
2019-08-28 |
Beijing Percans Oncology Co. Ltd. |
Tumor cell suspension cultures and related methods
|
JP7305352B2
(en)
*
|
2016-03-31 |
2023-07-10 |
武田薬品工業株式会社 |
isoquinolinyltriazolone complex
|
JP7112331B2
(en)
|
2016-04-01 |
2022-08-03 |
セージ セラピューティクス, インコーポレイテッド |
Oxysterols and their uses
|
US10752653B2
(en)
|
2016-05-06 |
2020-08-25 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
EP3454858A4
(en)
|
2016-05-09 |
2020-01-15 |
Aldeyra Therapeutics, Inc. |
Combination treatment of ocular inflammatory disorders and diseases
|
US20190030170A1
(en)
*
|
2016-05-10 |
2019-01-31 |
Vireo Health LLC |
Cannabinoid formulations with improved solubility
|
CA2969295A1
(en)
|
2016-06-06 |
2017-12-06 |
Pfizer Inc. |
Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
|
DK3481846T3
(en)
|
2016-07-07 |
2021-08-16 |
Sage Therapeutics Inc |
11-SUBSTITUTED 24-HYDROXYSTEROLS FOR USE IN THE TREATMENT OF NMDA-RELATED CONDITIONS
|
CA3030413A1
(en)
|
2016-07-11 |
2018-01-18 |
Sage Therapeutics, Inc. |
C17, c20, and c21 substituted neuroactive steroids and their methods of use
|
EP3481844B1
(en)
|
2016-07-11 |
2024-04-17 |
Sage Therapeutics, Inc. |
C7, c12, and c16 substituted neuroactive steroids and their methods of use
|
SG11201811412XA
(en)
|
2016-07-29 |
2019-02-27 |
Pfizer |
Cyclic peptides as c5 a receptor antagonists
|
US20180042903A1
(en)
|
2016-08-11 |
2018-02-15 |
Ovid Therapeutics Inc. |
Methods and compositions for treatment of epileptic disorders
|
MX2019001849A
(en)
|
2016-08-15 |
2019-05-09 |
Pfizer |
Pyridopyrimdinone cdk2/4/6 inhibitors.
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
EP3519422B1
(en)
|
2016-09-30 |
2022-08-31 |
Sage Therapeutics, Inc. |
C7 substituted oxysterols and these compounds for use as nmda modulators
|
WO2018068832A1
(en)
|
2016-10-11 |
2018-04-19 |
Euro-Celtique S.A. |
Hodgkin lymphoma therapy
|
DK3529257T3
(en)
|
2016-10-18 |
2023-08-07 |
Sage Therapeutics Inc |
OXYSTEROLS AND METHODS OF USING THEREOF
|
KR102521573B1
(en)
|
2016-10-18 |
2023-04-14 |
세이지 테라퓨틱스, 인크. |
Oxysterols and methods of their use
|
CA3043979A1
(en)
|
2016-11-18 |
2018-05-24 |
Aicuris Anti-Infective Cures Gmbh |
Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
US11472776B2
(en)
|
2016-12-20 |
2022-10-18 |
Oligomerix, Inc. |
Quinazolinones that inhibit the formation of tau oligomers and their method of use
|
SG11201906417RA
(en)
|
2017-01-20 |
2019-08-27 |
Pfizer |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
|
JP6778833B2
(en)
|
2017-01-20 |
2020-11-04 |
深▲チェン▼市塔吉瑞生物医薬有限公司Shenzhen TargetRx, Inc. |
(Hetero) arylamide compounds for suppressing kinase activity
|
WO2018133827A1
(en)
|
2017-01-20 |
2018-07-26 |
深圳市塔吉瑞生物医药有限公司 |
(hetero)arylamide compound for inhibiting protein kinase activity
|
RU2726631C1
(en)
|
2017-01-23 |
2020-07-15 |
Пфайзер Инк. |
Heterocyclic spiro compounds as magl inhibitors
|
WO2018146698A1
(en)
|
2017-02-07 |
2018-08-16 |
Biophore India Pharmaceuticals Pvt. Ltd. |
Improved method for the preparation of sulfobutylether beta cyclodextrin sodium
|
AU2018234919A1
(en)
|
2017-03-16 |
2019-09-19 |
Aldeyra Therapeutics, Inc. |
Polymorphic compounds and uses thereof
|
DK3600312T3
(en)
|
2017-03-26 |
2023-07-31 |
Takeda Pharmaceuticals Co |
PIPERIDINYL AND PIPERAZINYL SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6
|
KR102444482B1
(en)
|
2017-04-01 |
2022-09-16 |
셍커 파마슈티컬스 (지앙수) 엘티디. |
1H-imidazo[4,5-H]quinazoline compounds as protein kinase inhibitors
|
US20180318249A1
(en)
|
2017-05-03 |
2018-11-08 |
Cydex Pharmaceuticals, Inc. |
Composition containing cyclodextrin and busulfan
|
GB201709405D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating ovarian cancer
|
GB201709402D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating t-pll
|
GB201709403D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating sarcoma
|
GB201709406D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro-Cletique S A |
Compounds for treating TNBC
|
JOP20180057A1
(en)
|
2017-06-15 |
2019-01-30 |
Takeda Pharmaceuticals Co |
Tetrahydropyridopyrazine modulators of gpr6
|
MX2019015468A
(en)
|
2017-06-22 |
2020-08-03 |
Curadev Pharma Ltd |
Small molecule modulators of human sting.
|
CN108623576B
(en)
|
2017-06-26 |
2021-01-08 |
深圳市塔吉瑞生物医药有限公司 |
Indazole compound for inhibiting kinase activity and composition and application thereof
|
CN110759908B
(en)
|
2017-06-26 |
2021-03-12 |
深圳市塔吉瑞生物医药有限公司 |
N-benzenesulfonyl benzamide compound for inhibiting Bcl-2 protein and composition and application thereof
|
EP3651734A1
(en)
|
2017-07-11 |
2020-05-20 |
Gilead Sciences, Inc. |
Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
|
KR20200038286A
(en)
|
2017-08-11 |
2020-04-10 |
셍커 파마슈티컬스 (지앙수) 엘티디. |
1H-pyrazolo [4,3-H] quinazoline compounds acting as protein phosphatase inhibitors
|
EP3653622B1
(en)
|
2017-08-30 |
2022-12-28 |
Shenzhen TargetRx, Inc. |
Aminopyrimidine compound and composition comprising same and use thereof
|
TWI808092B
(en)
|
2017-08-30 |
2023-07-11 |
中國大陸商北京軒義醫藥科技有限公司 |
Cyclic di-nucleotides as stimulator of interferon genes modulators
|
EP3680236A4
(en)
|
2017-09-05 |
2021-04-21 |
Bioardis LLC |
Aromatic derivative, preparation method for same, and medical applications thereof
|
CA3074304A1
(en)
|
2017-09-11 |
2019-03-14 |
Krouzon Pharmaceuticals, Inc. |
Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
|
TW201920108A
(en)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(cyano-substituted benzyl or pyridinylmethyl)-3-hydroxypicolinamide derivatives
|
MX2020003425A
(en)
|
2017-10-10 |
2020-07-29 |
Aldeyra Therapeutics Inc |
Treatment of inflammatory disorders.
|
US20210228596A1
(en)
|
2017-10-12 |
2021-07-29 |
Sage Therapeutics, Inc. |
Method of treating cns disorders with neurosteroids and gabaergic compounds
|
KR20200096596A
(en)
|
2017-12-08 |
2020-08-12 |
세이지 테라퓨틱스, 인크. |
Deuterated 21-[4-cyano-pyrazole-1-yl]-19-nor-pregan-3 for the treatment of CNS disorders. Alpha-ol-20-one derivative
|
WO2019120094A1
(en)
|
2017-12-21 |
2019-06-27 |
深圳市塔吉瑞生物医药有限公司 |
Arylphosphine oxides for inhibiting kinase activity
|
CN109627263B
(en)
|
2017-12-21 |
2022-05-20 |
深圳市塔吉瑞生物医药有限公司 |
Diphenylaminopyrimidine compounds for inhibiting kinase activity
|
EP3730503A4
(en)
|
2017-12-21 |
2021-05-05 |
Shenzhen TargetRx, Inc. |
Antiviral nucleoside reverse transcriptase inhibitor
|
WO2019120071A1
(en)
|
2017-12-21 |
2019-06-27 |
深圳市塔吉瑞生物医药有限公司 |
Novel antiviral nucleoside reverse transcriptase inhibitor
|
JP2021506904A
(en)
|
2017-12-22 |
2021-02-22 |
セージ セラピューティクス, インコーポレイテッド |
Compositions and Methods for the Treatment of CNS Disorders
|
IL310454A
(en)
|
2017-12-22 |
2024-03-01 |
Sage Therapeutics Inc |
Compositions and methods for treating cns disorders
|
JP2021510695A
(en)
|
2018-01-12 |
2021-04-30 |
セージ セラピューティクス, インコーポレイテッド |
Bruises, oxa, and thia-pregnane-20-on-3α-ol compounds for use in the treatment of CNS disorders
|
WO2019145552A1
(en)
|
2018-01-29 |
2019-08-01 |
Phytoplant Research S.L |
Methods of purifying cannabinoids using liquid:liquid chromatography
|
TW201942115A
(en)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents
|
TW201942116A
(en)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
Tetrahydroquinazoline derivatives useful as anticancer agents
|
CN112236423B
(en)
|
2018-03-01 |
2024-02-06 |
武田药品工业株式会社 |
Piperidinyl-3- (aryloxy) propanamides and propionic acid esters
|
TWI741268B
(en)
|
2018-03-15 |
2021-10-01 |
美商輝瑞股份有限公司 |
Cyclopentane-based modulators of sting (stimulator of interferon genes)
|
WO2019201194A1
(en)
|
2018-04-16 |
2019-10-24 |
深圳市塔吉瑞生物医药有限公司 |
Substituted pyrrolotriazine compound, pharmaceutical composition thereof and use thereof
|
US11358973B2
(en)
|
2018-04-16 |
2022-06-14 |
Shenzhen Targetrx, Inc. |
Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity
|
MX2020011294A
(en)
|
2018-04-26 |
2020-11-18 |
Pfizer |
2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors.
|
JP2021525809A
(en)
|
2018-05-30 |
2021-09-27 |
コンバート ファーマシューティカルズ エス.エー. |
Prodrugs and their medical use
|
CA3101975A1
(en)
|
2018-06-01 |
2019-12-05 |
Bayer Cropscience Lp |
Stabilized fungicidal composition comprising cyclodextrin
|
WO2019243823A1
(en)
|
2018-06-21 |
2019-12-26 |
Curadev Pharma Limited |
Azaheterocyclic small molecule modulators of human sting
|
CN110194772B
(en)
|
2018-07-02 |
2022-04-05 |
深圳市塔吉瑞生物医药有限公司 |
Alkynyl (hetero) aromatic ring compounds for inhibiting protein kinase activity
|
EP3816162A4
(en)
|
2018-07-12 |
2021-08-11 |
Shenzhen TargetRx, Inc. |
Diarylpyrazole compound, composition comprising same, and use thereof
|
CN110272426B
(en)
|
2018-07-17 |
2022-05-31 |
深圳市塔吉瑞生物医药有限公司 |
Alkynyl (hetero) aromatic ring compounds for inhibiting protein kinase activity
|
US20210309669A1
(en)
|
2018-07-19 |
2021-10-07 |
Pfizer Inc. |
Heterocyclic Spiro Compounds As MAGL Inhibitors
|
WO2020033344A1
(en)
|
2018-08-06 |
2020-02-13 |
Aldeyra Therapeutics, Inc. |
Polymorphic compounds and uses thereof
|
WO2020068986A1
(en)
|
2018-09-25 |
2020-04-02 |
Aldeyra Therapeutics, Inc. |
Formulations for treatment of dry eye disease
|
WO2020076728A1
(en)
|
2018-10-08 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
|
WO2020073862A1
(en)
|
2018-10-10 |
2020-04-16 |
深圳市塔吉瑞生物医药有限公司 |
Dihydroimidazopyrazinone compound, composition including same, and use thereof
|
BR112021009428A2
(en)
|
2018-10-12 |
2021-08-31 |
Sage Therapeutics, Inc. |
NEUROACTIVE STEROIDS REPLACED AT POSITION 10 BY A CYCLIC GROUP FOR USE IN THE TREATMENT OF CNS DISORDERS
|
EP3867261A1
(en)
|
2018-10-19 |
2021-08-25 |
Sage Therapeutics, Inc. |
9(11)-unsaturated neuroactive steroids and their methods of use
|
US11142525B2
(en)
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
JP2022510628A
(en)
|
2018-11-29 |
2022-01-27 |
ファイザー・インク |
Pyrazole as a regulator of hemoglobin
|
CN113383004A
(en)
|
2018-12-05 |
2021-09-10 |
萨奇治疗股份有限公司 |
Neuroactive steroids and methods of use thereof
|
US20220017539A1
(en)
|
2018-12-06 |
2022-01-20 |
Shenzhen Targetrx, Inc. |
Substituted pyrazolo[1,5-a]pyridine compound, composition containing the same and use thereof
|
WO2020118142A1
(en)
|
2018-12-07 |
2020-06-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of pospartum depression
|
WO2020125391A1
(en)
|
2018-12-21 |
2020-06-25 |
深圳市塔吉瑞生物医药有限公司 |
Aminopyrimidine compound used for inhibiting activity of protein kinase
|
EP3898646A1
(en)
|
2018-12-21 |
2021-10-27 |
Sage Therapeutics, Inc. |
3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
|
WO2020141224A1
(en)
|
2019-01-04 |
2020-07-09 |
Sq Innovation Ag |
Pharmaceutical compositions of furosemide and uses thereof
|
EP3911331A4
(en)
|
2019-01-14 |
2023-01-18 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Tetrazolone substituted steroids and use thereof
|
TWI732431B
(en)
|
2019-01-23 |
2021-07-01 |
美商輝瑞股份有限公司 |
Polymorph
|
AU2020213761C1
(en)
|
2019-01-31 |
2023-08-10 |
Pfizer Inc. |
3-carbonylamino-5-cyclopentyl-1 Fi-pyrazole compounds having inhibitory activity on CDK2
|
JP7323218B2
(en)
|
2019-02-18 |
2023-08-08 |
深▲チェン▼市塔吉瑞生物医薬有限公司 |
Substituted Fused Aromatic Ring Derivatives, Compositions Thereof, and Uses Thereof
|
WO2020173457A1
(en)
|
2019-02-27 |
2020-09-03 |
深圳市塔吉瑞生物医药有限公司 |
Substituted pyrazole compounds, compositions containing same, and use thereof
|
TW202102498A
(en)
|
2019-03-22 |
2021-01-16 |
日商武田藥品工業股份有限公司 |
Pyridine-fused imidazole and pyrrole derivatives as ripk2 inhibitors
|
WO2020198064A1
(en)
|
2019-03-26 |
2020-10-01 |
Aldeyra Therapeutics, Inc. |
Ophthalmic formulations and uses thereof
|
EP3946606A1
(en)
|
2019-03-27 |
2022-02-09 |
Insilico Medicine IP Limited |
Bicyclic jak inhibitors and uses thereof
|
CN114072393A
(en)
|
2019-04-29 |
2022-02-18 |
索伦特治疗有限责任公司 |
3-amino-4H-benzo [ E ] [1,2,4] thiadiazine 1, 1-dioxide derivatives as MRGX2 inhibitors
|
WO2020243488A1
(en)
|
2019-05-31 |
2020-12-03 |
Sage Therapeutics, Inc. |
Neuroactive steroids and compositions thereof
|
CN112047938B
(en)
|
2019-06-06 |
2022-11-22 |
北京泰德制药股份有限公司 |
2,4, 6-trisubstituted pyrimidine compounds as ATR kinase inhibitors
|
CA3144701A1
(en)
|
2019-06-27 |
2020-12-30 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
WO2020264512A1
(en)
|
2019-06-27 |
2020-12-30 |
Sage Therapeutics, Inc. |
Compounds for treating cns disorders
|
EP3990469A1
(en)
|
2019-06-27 |
2022-05-04 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
EP4003961A2
(en)
|
2019-07-25 |
2022-06-01 |
Curadev Pharma Pvt. Ltd. |
Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
|
CA3145923A1
(en)
|
2019-08-05 |
2021-02-11 |
David Czekai |
Ganaxolone for use in treatment of status epilepticus
|
US20230000997A1
(en)
|
2019-08-06 |
2023-01-05 |
L.E.A.F. Holdings Group Llc |
Processes of preparing polyglutamated antifolates and uses of their compositions
|
US20220306659A1
(en)
|
2019-08-23 |
2022-09-29 |
Beijing Tide Pharmaceutical Co., Ltd. |
Compound inhibiting and inducing degradation of egfr and alk
|
WO2021055326A1
(en)
|
2019-09-16 |
2021-03-25 |
Takeda Pharmaceutical Company Limited |
Azole-fused pyridazin-3(2h)-one derivatives
|
CA3155569A1
(en)
|
2019-09-25 |
2021-04-01 |
Pfizer Inc. |
Polyheterocyclic modulators of sting (stimulator of interferon genes)
|
WO2021057877A1
(en)
|
2019-09-26 |
2021-04-01 |
深圳市塔吉瑞生物医药有限公司 |
Substituted aromatic fused ring derivative and composition comprising same, and use thereof
|
JP2023502889A
(en)
|
2019-11-01 |
2023-01-26 |
上海科技大学 |
EED INHIBITOR, METHOD OF MANUFACTURE THEREOF AND USE THEREOF
|
MX2022006014A
(en)
|
2019-12-06 |
2022-06-22 |
Marinus Pharmaceuticals Inc |
Ganaxolone for use in treating tuberous sclerosis complex.
|
WO2021121261A1
(en)
|
2019-12-16 |
2021-06-24 |
北京泰德制药股份有限公司 |
Compound for inhibiting and inducing degradation of egfr kinase
|
US20230122967A1
(en)
|
2020-01-17 |
2023-04-20 |
Shengke Pharmaceuticals (Jiangsu) Ltd. |
Novel compounds as inhibitors of pcsk9
|
KR20220141328A
(en)
|
2020-02-12 |
2022-10-19 |
큐라데브 파마 프라이버트 리미티드 |
Small molecule STING antagonists
|
CN115551874A
(en)
|
2020-03-18 |
2022-12-30 |
萨奇治疗股份有限公司 |
Neuroactive steroids and methods of use thereof
|
AR121682A1
(en)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
N-(HETEROCYCLIL AND HETEROCYCLILALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS
|
AR121683A1
(en)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
N-HETEROARYLALKYL-2-(HETEROCYCLIL AND HETEROCYCLILMETHYL)ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS
|
JP2021167301A
(en)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
|
CN115698004A
(en)
|
2020-05-01 |
2023-02-03 |
辉瑞公司 |
Azalactam compounds as HPK1 inhibitors
|
WO2021225968A1
(en)
|
2020-05-04 |
2021-11-11 |
Takeda Pharmaceutical Company Limited |
Luminally-acting n-(piperidin-4-yl)benzamide derivatives
|
WO2021224818A1
(en)
|
2020-05-08 |
2021-11-11 |
Pfizer Inc. |
Isoindolone compounds as hpk1 inhibitors
|
KR20230012584A
(en)
|
2020-05-20 |
2023-01-26 |
베이징 타이드 파마슈티컬 코퍼레이션 리미티드 |
2,4,6-trisubstituted pyrimidine compounds as ATR kinase inhibitors
|
US20230250129A1
(en)
|
2020-06-24 |
2023-08-10 |
Sage Therapeutics, Inc. |
Neuroactive steroids and compositions thereof
|
TW202214641A
(en)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2 mutation inhibitors
|
BR112023000654A2
(en)
|
2020-07-13 |
2023-04-25 |
Beijing Tide Pharmaceutical Co Ltd |
PYRAZOLOPYRMIDINE COMPOUND USED AS AN ATR KINASE INHIBTOR
|
WO2022013692A1
(en)
|
2020-07-15 |
2022-01-20 |
Pfizer Inc. |
Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride
|
WO2022013691A1
(en)
|
2020-07-15 |
2022-01-20 |
Pfizer Inc. |
Polymorph of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
GB202011812D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
GB202011811D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
JP2023538774A
(en)
|
2020-08-27 |
2023-09-11 |
晟科薬業(江蘇)有限公司 |
1H-imidazo[4,5-H]quinazoline compounds as novel selective FLT3 inhibitors
|
TW202229239A
(en)
|
2020-09-23 |
2022-08-01 |
日商武田藥品工業股份有限公司 |
3-(6-aminopyridin-3-yl)benzamide derivatives as ripk2 inhibitors
|
JP2023550653A
(en)
|
2020-11-25 |
2023-12-04 |
セージ セラピューティクス, インコーポレイテッド |
Compositions and methods for treating disorders of the CNS
|
IL306034A
(en)
|
2021-03-18 |
2023-11-01 |
Pfizer |
Modulators of sting (stimulator of interferon genes)
|
CA3213593A1
(en)
|
2021-03-31 |
2022-10-06 |
Sevenless Therapeutics Limited |
Sos1 inhibitors and ras inhibitors for use in the treatment of pain
|
GB202104609D0
(en)
|
2021-03-31 |
2021-05-12 |
Sevenless Therapeutics Ltd |
New Treatments for Pain
|
CN117545751A
(en)
|
2021-04-07 |
2024-02-09 |
生命爱科 |
2, 4-diaminopyrimidine derivatives as ULK1/2 inhibitors and their use
|
US11649299B2
(en)
|
2021-06-10 |
2023-05-16 |
Cyclolab Cyclodextrin Research And Development Laboratory Ltd. |
Purification of sulfobutylated cyclodextrins with specific ion exchange resins
|
CA3225045A1
(en)
|
2021-06-26 |
2022-12-29 |
Array Biopharma Inc. |
Her2 mutation inhibitors
|
CN117693516A
(en)
|
2021-07-28 |
2024-03-12 |
萨奇治疗股份有限公司 |
Crystalline forms of neuroactive steroid
|
AU2022326885A1
(en)
|
2021-08-11 |
2024-02-15 |
Curadev Pharma Pvt. Ltd. |
Small molecule urea derivatives as sting antagonists
|
CA3228528A1
(en)
|
2021-08-11 |
2023-02-16 |
Monali BANERJEE |
Small molecule sting antagonists
|
WO2023049295A1
(en)
|
2021-09-22 |
2023-03-30 |
Sage Therapeutics, Inc. |
Deuterated positive nmda-modulating compounds and methods of use thereof
|
WO2023099072A1
(en)
|
2021-12-01 |
2023-06-08 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Compounds
|
WO2023144692A1
(en)
*
|
2022-01-25 |
2023-08-03 |
Leiutis Pharmaceuticals Llp |
Novel naproxen sodium preparations for parenteral
|
WO2023156966A1
(en)
|
2022-02-18 |
2023-08-24 |
Beren Therapeutics P.B.C. |
Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
|
WO2023187677A1
(en)
|
2022-03-30 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
|
TW202345838A
(en)
|
2022-04-07 |
2023-12-01 |
日商武田藥品工業股份有限公司 |
Fused pyridazine derivatives
|
WO2023205165A1
(en)
*
|
2022-04-22 |
2023-10-26 |
Brii Biosciences Offshore Limited |
A polymyxin composition and methods for producing the same
|
EP4332087A1
(en)
|
2022-04-29 |
2024-03-06 |
Beijing Jitai Pharmaceutical Technology Co., Ltd. |
Lipid nanoparticles
|
CN116969851A
(en)
|
2022-04-29 |
2023-10-31 |
北京剂泰医药科技有限公司 |
Ionizable lipid compounds
|
WO2024026337A1
(en)
|
2022-07-27 |
2024-02-01 |
Sage Therapeutics, Inc. |
Crystalline forms of a neuroactive steroid
|
US20240109915A1
(en)
|
2022-07-29 |
2024-04-04 |
Pfizer Inc. |
Novel acc inhibitors
|
WO2024033845A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
WO2024059608A1
(en)
|
2022-09-15 |
2024-03-21 |
Sage Therapeutics, Inc. |
Deuterated neuroactive steroids
|
WO2024074827A1
(en)
|
2022-10-05 |
2024-04-11 |
Sevenless Therapeutics Limited |
New treatments for pain
|